Core Viewpoint - The company, New Wave Pharmaceuticals (06108), has announced a placement agreement to issue up to 33.432 million shares at a price of HKD 0.225 per share, which represents a discount to the market price [1] Group 1: Placement Details - The maximum number of shares to be placed represents approximately 20.00% of the company's existing issued share capital as of the announcement date [1] - The placement price of HKD 0.225 per share reflects an 8.16% discount to the closing price of HKD 0.245 on the last trading day [1] - The placement price also shows a 10.57% discount compared to the average closing price of approximately HKD 0.2516 over the five trading days preceding the last trading day [1] Group 2: Financial Implications - The total gross proceeds from the placement are expected to be approximately HKD 7.5 million, with net proceeds estimated at around HKD 7.4 million after deducting placement fees and other expenses [1] - The net proceeds from the placement will be fully utilized for acquiring additional distribution rights related to the company's core business [1]

Group 1 - The company, New Horizon Health (06108.HK), announced a placement agreement with a placement agent to issue up to 33.43 million shares at a price of HKD 0.225 per share, which represents an approximate discount of 8.16% compared to the closing price of HKD 0.245 reported by the Stock Exchange [1] - The total gross proceeds from the placement are expected to be around HKD 7.5 million, with net proceeds estimated at approximately HKD 7.4 million after deducting placement fees and other expenses related to the placement [1] - The net proceeds from the placement are intended to be used for acquiring additional distribution rights for the company's core business [1]